Skip to main content

Table 2 Clinical variables (median, 25 and 75 percentile, mean ± SD at baseline, after 3 and 6 months, differences and statistical analysis

From: Adjunctive use of essential oils following scaling and root planing –a randomized clinical trial

N test group  =  23

N control group  =  23

Baseline

3 months

6 months

Difference t0-t3

Difference t0-t6

BoP (%)

   Test

   Control

17.0 (13.0, 19.0) ***

16.0 (13.0, 19.0) ***

6.0 (4.0, 9.0) *** ††

9.0 (5.0, 12.0) ***

12.0 (9.0, 14.0) ***

11.0 (8.0, 17.0) ***

10.0 (8.0, 12.0) *** †

9.0 (6.0, 11.0) ***

5.0 (3.0, 8.0) ***

4.0 (2.0, 7.0) ***

   Test

   Control

16.5 ± 4.0

16.7 ± 5.5

6.2 ± 3.0

8.7 ± 3.7

11.5 ± 4.9

13.0 ± 6.7

10.3 ± 3.1

8.0 ± 4.0

5.0 ± 4.0

3.7 ± 5.6

SBI (%)

   Test group

   Control group

18.0 (14.0, 23.0) ***

16.0 (14.0, 21.0) ***

12.0 (8.0, 15.0) ***

11.0 (7.0, 15.0) ***

13.0 (11.0, 18.0) ***

13.0 (11.0, 15.0) ***

7.0 (4.0, 11.0) ***

8.0 (4.0, 12.0) ***

4.0 (0.0, 8.0) **

4.0 (3.0, 8.0) **

   Test

   Control

18.7 ± 6.5

18.1 ± 5.6

11.8 ± 4.4

10.3 ± 4.3

13.4 ± 5.2

13.4 ± 3.8

6.8 ± 5.2

7.8 ± 5.4

5.2 ± 5.7

4.7 ± 5.9

Mean PD (mm)

   Test

   Control

3.3 (3.1, 3.6) ***

3.2 (3.1, 3.5) ***

2.1 (2.0, 2.2) *** ††

2.2 (2.0, 2.5) ***

2.2 (2.0, 2.3) *** ††

2.3 (2.1, 2.5) ***

1.2 (0.8, 1.2) *** †

1.0 (0.9, 1.5) ***

1.1 (0.8, 1.2) ***

1.0 (0.8, 1.5) ***

   Test

   Control

3.3 ± 0.4

3.3 ± 0.3

2.1 ± 0.3

2.3 ± 0.2

2.2 ± 0.2

2.3 ± 0.3

1.2 ± 0.3

1.0 ± 0.3

1.1 ± 0.3

1.0 ± 0.3

Mean AL (mm)

   Test group

   Control group

3.5 (3.3, 3.7) ***

3.5 (3.3, 3.7) ***

2.5 (2.4, 2.6) *** ††

2.8 (2.5, 2.9) ***

2.6 (2.5, 2.7) *** ††

2.8 (2.7, 3.0) ***

0.9 (0.8, 1.1) *** †††

0.7 (0.6, 0.8) ***

0.9 (0.7, 1.0) *** †††

0.6 (0.5, 0.7) ***

   Test

   Control

3.5 ± 0.2

3.4 ± 0.3

2.5 ± 0.3

2.7 ± 0.3

2.6 ± 0.2

2.8 ± 0.3

1.0 ± 0.3

0.7 ± 0.2

0.9 ± 0.2

0.6 ± 0.2

Sites PD > 5 mm (n)

   Test

   Control

18.0 (13.0,27.0)

19.0 (9.0, 25.0)

0.0 (0.0, 2.0)

1.0 (0.0, 5.0)

0.0 (0.0, 2.0)

2.0 (0.0, 6.0)

17.0 (13.0, 26.0)

17.0 (8.0, 22.0)

18.0 (13.0, 25.0)

16.0 (7.0, 22.0)

   Test

   Control

18.7 ± 10.3

19.4 ± 13.0

1.1 ± 1.7

2.7 ± 3.3

1.3 ± 2.2

3.4 ± 4.2

17.6 ± 9.2

16.7 ± 10.2

17.4 ± 8.7

16.0 ± 9.9

Mean sites PD  >  5 mm (n)

   Test

   Control

5.3 (5.0, 5.5)

5.3 (5.0, 5.5)

3.0 (2.8, 3.3)

3,0 (2.8, 3.3)

3.0 (2.8, 3.5)

3.0 (2.8, 3.3)

2.5 (2.3, 2.5)

2.3 (2.0, 2.5)

2.3 (2.0, 2.5)

2.3 (2.0, 2.3)

   Test

   Control

5.3 ± 0.4

5.3 ± 0.4

3.0 ± 0.4

3.0 ± 0.3

3.1 ± 0.4

3.1 ± 0.3

2.3 ± 0.2

2.3 ± 0.3

2.2 ± 0.3

2.2 ± 0.4

Sites AL > 5 mm (n)

   Test

   Control

21.0 (14.0, 31.0)

21.0 (12.0, 27.0)

2.0 (0.0, 3.0)

2.0 (0.0, 6.0)

1.0 (0.0, 3.0)

3.0 (0.0, 8.0)

21.0 (14.0, 27.0)

16.0 (12.0, 24.0)

21.0 (14.0, 27.0)

16.0 (9.0, 23.0)

Test Control

21.3 ± 11.5

22.3 ± 14.7

2.1 ± 3.3

3.4 ± 4.2

2.4 ± 3.7

4.3 ± 4.4

19.2 ± 9.5

18.9 ± 11.7

18.9 ± 9.1

18.0 ± 11.7

Mean sites AL > 5 mm (n)

   Test

   Control

4.0 (4.0, 4.3)

4.0 (4.0, 4.3)

2.8 (2.8, 3.0)

3.0 (2.8, 3.0)

3.0 (3.0, 3.0)

3.0 (3.0, 3.3)

1.3 (1.3, 1.5)

1.3 (1.0, 1.5)

1.0 (1.0, 1.3)

1.0 (0.8, 1.3)

   Test

   Control

4.2 ± 0.3

4.1 ± 0.2

2.9 ± 0.2

2.9 ± 0.3

3.1 ± 0.2

3.1 ± 0.2

1.3 ± 0.2

1.2 ± 0.3

1.1 ± 0.3

1.0 ± 0.2

  1. Wilcoxon signed rank test: significant longitudinal changes t3 - t0, t6 - t0 within each group
  2. ** 0.01  <  p  <  0.05, *** p  <  0.001
  3. Mann Whitney test between the groups (test-control): † 0.05  <  p  <  0.1, †† 0.01  <  p  <  0.05, †††    <  0.001
Back to article page

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us